Accepted Manuscript

The Comparative Evidence Basis for the Efficacy of Second-Generation Antidepressants in the Treatment of Depression in the US: A Bayesian Meta-Analysis of Food and Drug Administration Reviews


Rei Monden, Annelieke M. Roest, Don van Ravenzwaaij, Eric-Jan Wagenmakers, Richard Morey, Klaas J. Wardenaar, Peter de Jonge

PII: S0165-0327(17)32545-4 DOI: 10.1016/j.jad.2018.04.040

Reference: JAD 9694

To appear in: Journal of Affective Disorders

Received date: 8 December 2017
Revised date: 6 March 2018
Accepted date: 4 April 2018



Please cite this article as: Rei Monden, Annelieke M. Roest, Don van Ravenzwaaij, Eric-Jan Wagenmakers, Richard Morey, Klaas J. Wardenaar, Peter de Jonge, The Comparative Evidence Basis for the Efficacy of Second-Generation Antidepressants in the Treatment of Depression in the US: A Bayesian Meta-Analysis of Food and Drug Administration Reviews, *Journal of Affective Disorders* (2018), doi: 10.1016/j.jad.2018.04.040

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Highlights

- FDA approved antidepressants can be differentiated by strength of evidence for the efficacy by means of Bayesian approach.
- Bupropion and vilazodone showed weak evidence for the efficacy, based on the trial results registered at the FDA.
- Both the effect size and the evidence-load can be considered to prescribe an antidepressant.

Download English Version:

https://daneshyari.com/en/article/8815434

Download Persian Version:

https://daneshyari.com/article/8815434

<u>Daneshyari.com</u>